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ABSTRAK 
Pengenalan 
Masalah sembelit dan implikasinya telah menerima perhatian yang sedikit walaupun  
gangguan peristalsis usus ini sering berlaku di kalangan pesakit kritikal . Sembelit 
ditakrifkan sebagai kegagalan peristalsis usus untuk membuang air besar selama 3 hari 
berturut-turut. Keadaan ini boleh menimbulkan beberapa kesan buruk kepada pesakit kritikal 
seperti pesakit yang sembelit lebih sukar untuk diberhentikan daripada bantuan pernafasan 
mekanikal , jangkamasa median tinggal di unit rawatan rapi lebih lama dan ketidak toleransi 
kepada makanan enteral adalah lebih tinggi daripada pesakit bukan sembelit. 
 
Objektif 
Untuk membandingkan pembukaan usus di kalangan para pesakit yang menerima infusi 
neostigmine berbanding sirap lactulose untuk rawatan sembelit di ICU. 
 
Kaedah 
Ini adalah kajian prospektif. Pesakit yang menerima bantuan pernafasan yang memenuhi 
kriteria kajian dan dimasukkan ke ICU HUSM antara bulan Februari hingga Oktober 2015 
dipilih secara rawak untuk menerima sama ada infusi neostigmine 0.4-0.8 mg / jam atau 
sirap lactulose 15 mls TDS . Insiden pembukaan usus, masa untuk pembukaan usus pertama 
dan apa-apa kesan sampingan direkodkan. 
 xii 
 
Keputusan 
Seramai 40 pesakit secara rawak dibahagikan kepada 2 kumpulan, infusi neostigmine dan 
sirup lactulose dengan 20 pesakit dalam setiap kumpulan. Kumpulan infusi neostigmine 
mempunyai pembukaan usus dengan ketara (p-value = 0.027) dan jauh lebih cepat (p -value 
<0.001) berbanding kumpulan sirap lactulose . Tiada perbezaan purata yang ketara dari segi 
jangkamasa bantuan pernafasan mekanikal di antara dua kumpulan terapi (p-value = 0.542). 
Tiada komplikasi yang berlaku daripada infusi neostigmine. 
 
Kesimpulan 
Infusi neostigmine adalah berkesan untuk rawatan sembelit di ICU berbanding dengan 
rawatan sirup lactulose. Rawatan intravena infusi neostigmine sehingga 0.8 mg / jam untuk 
pesakit kritikal dilihat sebagai selamat. 
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ABSTRACT 
 
Introduction 
Constipation and its implications have received very little attention even though this 
gastrointestinal motility disorders are common in critically ill patients. Constipation is 
defined as failure of the bowel to open for 3 consecutive days. This condition can give rise 
few adverse implications in critically ill patients such as more constipated patient failed to 
wean from mechanical ventilation, the median length of stay in intensive care increase and 
the proportion of enteral feeding intolerance were greater than non-constipated patients. 
 
Objectives 
To compare bowel opening between groups of patients who receive neostigmine infusion 
versus syrup lactulose for treatment of constipation in ICU. 
 
Methodology 
This is a prospective study. The ventilated patients who fulfilled the inclusion criteria and 
were admitted to HUSM ICU between February till October 2015 were randomly received 
either neostigmine infusions 0.4 – 0.8 mg/hour or syrup lactulose 15 mls TDS. Incidence of 
bowel opening, time to first bowel opening and any adverse reactions were recorded.  
                                                                                                                   
 xiv 
 
Results 
40 patients were randomized where 20 patients in each group either neostigmine infusion or 
syrup lactulose. Neostigmine infusion group significantly had bowel opening (p-
value=0.027) and markedly had faster onset of bowel opening (p-value<0.001) compared to 
syrup lactulose group. There was no significant mean different in term of length of 
mechanical ventilation between two group of therapy (p-value=0.542). No complications 
occurred from the neostigmine infusion. 
 
Conclusion 
Neostigmine infusion was effective for treatment of constipation in ICU compared than 
standard therapy syrup lactulose. Continuous intravenous neostigmine infusion of up to 0.8 
mg / hour to critically ill patients appears to be safe.  
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CHAPTER 1: INTRODUCTION 
 
1.1: Background 
 
Gastrointestinal motility disturbances are one of the common problems among patients in 
intensive care unit. Usually dysmotility abnormalities such as gastric emptying and 
diarrhoea get more attention during daily treatment. These two problems are well studied 
and have a considerable impact in critically ill patient’s prognoses. However constipation 
problem tend to be ignored and has received much less attention in clinical studies. 
Constipation among patient in intensive care unit supposedly needs to be well treated 
because this condition also has its own implications toward the patients. Therefore 
effectiveness in treating constipation is also important to avoid or reduce adverse condition 
that can arise from constipation problem.  
Patients in ICU are a special group of patients which are their condition, nature of illness 
and treatment that they received, make them prone to get hypomotility disorder of 
gastrointestinal tract include constipation. In ICU, gastrointestinal motility can be altered by 
sedation, analgesics, anticholinergics, immobility, surgery, enteral feeding, head and spinal 
injuries, inflammation and sepsis (Nguyen et al., 2013). 
There are various medications that been used to treat constipation. Common medications are 
syrup lactulose and bisocodyl (Hsieh, 2005).  Still not commonly use in Intensive Care Unit 
(ICU), neostigmine also is one of the medication that can be used to treat constipation 
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(Schiller, 2001).  Therefore, this study wants to know the comparison in term of 
effectiveness between standard therapy syrup lactulose and neostigmine infusion for 
treatment of constipation among patients in ICU.  
This study was conducted at ICU Hospital Universiti Sains Malaysia (HUSM). There are 
three categories of ICU at HUSM; General ICU, Surgical ICU and Neuro ICU which 
consisted of 10 beds, 4 beds and 12 beds respectively. However most of the subjects were 
Neuro ICU patients in view of they fulfill the study criteria most of the time. 
Progressiveness of the study is maintained by getting helping from the trained medical 
officer in anaesthesia and intensive care unit department as well as trained ICU staffs. 
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1.2: Problem statements. 
 
Problem statement 1:  
 
Constipation among ICU patients is a common hypomotility gastrointestinal disorder that 
can give rise to few implications toward critically ill patients. 
 
Problem statement 2: 
 
Medication that can effectively treat constipation are needed to avoid or reduce implications 
that can rise from this problem. Therefore it is important to know which medication that can 
effectively treat constipation, either standard therapy – syrup lactulose or neostigmine 
infusion. 
 
1.3: Research justification 
 
Previous studies reports suggested that neostigmine infusion was more effective in treating 
constipation among critically ill patient in ICU as compared to syrup lactulose. This study is 
crucial in providing more evidence of such finding in Malaysia hospital setting. The 
knowlegde gained from this study will provide information to support evidence-based 
practices on neostigmine infusion usage in ICU. 
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CHAPTER 2:   LITERATURE REVIEW 
 
2.1 Pharmacology of neostigmine 
 
2.1.1 Classification 
Neostigmine is an anticholinesterase drug. It is a quaternary ammonium compound that 
possesses a strongly basic carbamyl group. Chemically, neostigmine bromide is 3-
[(Dimethylcarbamoyl)oxy]-N,N,N trimethylanilinium bromide (Reilly et al., 2005). 
 
 
 
 
 
Figure 2.1 : Neostigmine structure (Reilly et al., 2005) 
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2.1.2 Mechanism of action.  
Neostigmine inhibit the enzyme acetylcholinesterase (true cholinesterase), which usually 
responsible for the rapid hydrolysis of the neurotransmitter acetylcholine to choline and 
acetic acid (Reilly et al., 2005). 
The acetylcholinesterase has two active sites, an anionic site and an esteratic site. Catalytic 
hydrolysis of acetylcholine occurs whereby the acetyl group is transferred to the esteratic 
site releasing a free choline molecule. Spontaneous hydrolysis of the enzyme follows and 
the acetylcholinesterase is reactivated (Nair et al., 2004). 
Neostigmine creates reversible inhibition of acetylcholinesterase by formation of a carbamyl 
ester complex at the esteratic site of the enzyme. This inhibition leads to greater availability 
of acetylcholine at its sites of action, which include preganglionic sympathetic and 
parasympathetic nerve endings and the NMJ. Carbamate-enzyme bond must be dissociated 
for the carbamylated acetylcholinesterase hydrolyzes acetylcholine. Half-time for 
Carbamylated acetylcholinesterase is 15 to 30 minutes (Reilly et al., 2005). 
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Figure. 2.2:  Mechanism of acetylcholine hydrolysis by acetylcholinesterase. (Schematic 
diagram from Nair et al. 2004)  
2.1.3 Uses 
The standard clinical uses of neostigmine as an anticholinesterase drug are antagonist-
assisted reversal of neuromuscular blockade produced by nondepolarizing neuromuscular-
blocking drugs, treatment of the CNS effects produced by certain drugs, treatment of 
myasthenia gravis, treatment of glaucoma, treatment of paralytic ileus and treatment for 
atony of the urinary bladder.  Intravenous dose is 0.05–0.07 mg kg¯ 1(Nair et al., 2004). 
2.1.4 Pharmacokinetics 
After a single bolus dose, the plasma concentrations of neostigmine reach a peak and decline 
rapidly during the first 5 to 10 minutes. The volume of distribution of neostigmine is in the 
range of 0.7 to 1.4 liters/kg, and the elimination half-times are 60 to 120 minutes.  
The clearance of anticholinesterase drugs is in the range of 8 to 16 mL/kg per minute, which 
is much greater than glomerular filtration rate (Reilly et al., 2005). 
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Neostigmine comprising a quaternary ammonium group is poorly lipid soluble and thus do 
not easily penetrate lipid cell membrane barriers such as the gastrointestinal tract or blood 
brain barrier. This explained neostigmine is poorly absorbed orally and oral bioavailability 
1-2% (Reilly et al., 2005). 
This anticholinesterase drug is actively secreted into the lumens of the renal tubules. 
Approximately 50 % of the elimination of neostigmine is by renal clearance. As a result, the 
elimination half-time of neostigmine is greatly prolonged by renal failure. In the failure of 
renal function, hepatic metabolism accounts for 50 % of a dose of neostigmine. 3-
hydroxyphenyltrimethylammonium is the principal metabolite for neostigmine. This 
metabolite has approximately one-tenth the antagonist activity of the parent compound 
(Reilly, 2015). 
2.1.5 Pharmacodynamics 
The pharmacologic effect of neostigmine as an anticholinesterase drug is expectable and 
reflects the accumulation of acetylcholine at muscarinic and nicotinic cholinergic receptors 
(nAChRs).  Depending on the purpose for administration of anticholinesterase drugs, these 
effects may be considered therapeutic or undesirable (Reilly et al., 2005). 
The cardiovascular effects of neostigmine reflect effects of accumulated acetylcholine at the 
heart (vagal effects), blood vessels, autonomic ganglia and postganglionic cholinergic nerve 
endings (Reilly et al., 2005). 
Bradycardia and/or bradydysrhythmia for example nodal and ventricular escape beats may 
occur. Bradycardia most likely reflects slowing of the conduction of cardiac impulses 
through the atrioventricular node. These cardiac effects of anticholinesterase drugs can be 
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reduced by the administration of an anticholinergic drug that blocks muscarinic receptors 
but not nAChRs. Reductions in systemic blood pressure that may accompany accumulation 
of acetylcholine presumably reflect reductions in systemic vascular resistance, although the 
coronary and pulmonary circulations may manifest an opposite response (Reilly et al., 
2005). 
Neostigmine enhances gastric fluid secretion by parietal cells and increases the motility of 
the entire gastrointestinal tract, particularly the large intestine. The action of 
anticholinesterase drug on gastrointestinal motility is due to the effects of accumulated 
acetylcholine on the ganglion cells of Auerbach‟s plexus and on smooth muscle fibers. 
Neostigmine 0.5 to 1 mg given subcutaneously may be effective in the treatment of paralytic 
ileus or atony of the urinary bladder. This treatment, however should not be used when there 
is present of mechanical obstruction of the gastrointestinal tract. The lower portion of the 
esophagus is stimulated by anticholinesterase drug, resulting in beneficial increase in tone 
and peristalsis in patients with achalasia (Reilly et al., 2005). 
As an anticholinesterase drug, neostigmine increases production of secretions of glands that 
are innervated by postganglionic cholinergic fibers. Such glands include the bronchial, 
lacrimal, sweat, salivary, gastric, intestine and acini pancreatic glands (Reilly et al., 2005)  
Smooth muscle fibers of bronchioles and ureters also been contracted by anticholinesterase 
drug. Cholinergic stimulation of the bronchi resulting bronchoconstriction and 
anticholinesterase drug has the potential to increase airway resistance (Reilly et al., 2005). 
Neostigmine if applied topically to the cornea can cause constriction of the sphincter of the 
iris (miosis) and ciliary muscle. Constriction of the ciliary muscle leads to inability to focus 
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for near vision. Interference with accommodation is normally shorter in duration than is 
miosis. Intraocular pressure decreases because the outflow of aqueous humor is facilitated 
(Reilly et al., 2005). 
 
2.2 Pharmacology of syrup lactulose 
 
2.2.1 Description 
Syrup lactulose is a synthetic disaccharide which is in solution form for oral administration. 
4-O-β-D galactopyranosyl-D- fructofuranose is a chemical name for lactulose.  
 
 
Figure 2.3: Syrup lactulose structure (Reilly et al., 2005). 
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Each 15 ml of lactulose solution contains 10 g lactulose (and less than 1.6g galactose, less 
than 1.2g lactose and 1.2g or less of other sugars). Recommended doses range from 10 – 20g 
per day (Reilly et al., 2005). 
2.2.2 Uses 
Lactulose is use for treatment of constipation. Number of bowel movements per day and the 
number of days on which bowel movements occurs increases with syrup lactulose therapy. 
Syrup lactulose also been use for ammonia detoxicant. It is used as an adjunct to protein 
restriction and supportive therapy for prevention and treatment of portal systemic 
encephalopathy (PSE) including hepatic pre-coma and coma (Reilly et al., 2005). 
2.2.3 Pharmacodynamics and pharmacokinetics 
No enzyme in human gastrointestinal tissue capable to hydrolyze disaccharide make the 
syrup lactulose is poorly absorbed from the gastrointestinal tract. Following oral 
administration, less than 3% absorbed from small bowel and negligible absorption from 
colon. Therefore, oral doses of syrup lactulose that reach the colon virtually unchanged. In 
the colon, colonic bacteria break down syrup lactulose primarily to lactic acid and also to 
small amount of formic and acetic acids. This result increase in osmotic pressure and slight 
acidification of the colonic content, subsequently increase in stool water content and softens 
the stool (Reilly et al., 2005). 
Acidification of colon contents inhibits the nonionic diffusion of ammonia from the colon 
into the blood. Since colon contents are more acidic than is blood, ammonia can diffuse 
from the blood into the colon. In the acidic environment, ammonia (NH3) is converted to 
ammonium ions (NH4+) thereby preventing its absorption. Finally lactulose expels the 
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trapped ammonium ions and possibly other nitrogenous substances from the colon (Reilly et 
al., 2005). 
Meanwhile, 24 to 48 hours may be required to produce the desired bowel movement. This is 
because syrup lactulose does not exert its effect until it reach the colon and transit time 
through colon maybe slow. The absorbed drug will be excreted in urine unchanged within 
24 hours (Reilly et al., 2005). 
2.2.4 Contraindications and precautions 
Syrup lactulose is contraindicated in patients who require a low galactose diet since syrup 
lactulose contains galactose (less than 1.6g / 15 ml). For the same reason, diabetes mellitus 
patient also should use syrup lactulose with caution in view of has risk of hyperglycaemia 
(Reilly et al., 2005). 
 
2.3 An overview of patients in Intensive Care Unit (ICU) 
 
An Intensive Care Unit is a specific area in the hospital, specially staffed and equipped unit, 
where patients with life-threatening illnesses or disorders are monitored and treated. It is 
dedicated to the observation, care and treatment of patients with life threatening illnesses, 
injuries or complications from which recovery is generally possible. The patients in 
Intensive Care Unit can be classified either surgical or medical patients. The common causes 
of ICU admission from surgical discipline are perioperative stabilization, postoperative 
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weaning, hypovolemic shock, septic shock and trauma – head injury, chest and cervical 
spine injury (Geok et al., 2012). 
The common causes of medical admission are septicaemic shock and acute respiratory 
failure requiring ventilator support. The patients with acute respiratory failure who were 
admitted to ICU require noninvasive or invasive mechanical ventilation.  
The first ICU in Malaysia was established in 1968. Since then, intensive care has developed 
rapidly and ICUs are now available in all tertiary care hospitals and selected secondary care 
hospitals in the Ministry of Health. There are wide varieties of critically ill patients managed 
in ICU which can be categorized as operative and non-operative patients. SOFA score is a 
scoring system which provides an estimation of ICU mortality. The other scores used for 
prediction of in hospital mortality were APACHE score and SAPS II score.  
 
2.4 Sequential Organ Failure Assessment (SOFA) 
 
The Sequential Organ Failure Assessment (SOFA) score was introduced in 1994 is one of 
the model that been developed to quantify the severity of patients‟ illness based on the 
degree of organ dysfunction; serially over the time (Arts et al., 2005).  SOFA; originally 
referred to as the “Sepsis – related Organ Failure Assessment Score” developed by a panel 
of expert from the European Society of Intensive Care Medicine,  based on review of the 
literature (Cabré et al., 2005).   
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The SOFA score is graded from 0 (normal) to 4 (most abnormal) according to the degree of 
dysfunction / failure. This tool composed of scores from six organ systems. These organ 
systems are respiratory (PaO2 / FiO2), cardiovascular (blood pressure, vasoactive drugs), 
renal (creatinine), hematological (platelet count), neurological (Glasgow Coma Scale) and 
liver (bilirubin) (Cabré et al., 2005).  
 An initial SOFA score up to 9 predicted a mortality of less than 33%, while an initial SOFA 
score of greater than 11 predicted a mortality rate of 95%. Independent of the initial value, 
an increase in SOFA score during first 48 hours of ICU admission predicts a mortality rate 
of at least 50 % (Ferreira et al., 2001) 
 
2.5 Normal gastrointestinal motility 
 
The gut has not only the most extensive immune system in the body but also the largest 
collection of neurons (up to 108 cells) outside the central nervous system in order to 
maintain fluid, electrolyte, and energy homeostasis by the assimilation of food (Holzer et al., 
2001) 
This enteric nervous system (ENS) is located within the bowel wall, covering from the 
esophagus to the internal anal sphincter. It is well organized in such a way that it can operate 
independently of the brain. The neurons of the ENS are organized in two main plexuses 
(Figure 2.4).  
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The myenteric plexus which is mainly regulates motility located between the longitudinal 
and circular muscle layers. Meanwhile the submucous plexus which is located between the 
circular muscle and the mucosa is involved in the regulation of mucosal processes 
(electrolyte and fluid secretion, mucus secretion, mucosal blood flow and neuroimmune 
interactions) (Schemann et al., 1999).  
 
 
Figure 2.4:. Schematic diagram showing the multiple innervation of the gastrointestinal (GI) 
tract by intrinsic enteric neurons originating in the myenteric plexus (MP) and submucosal 
plexus (SMP), extrinsic sensory neurons originating from the nodose ganglia (NG; vagal 
afferents) and dorsal root ganglia (DRG; spinal afferents), and autonomic efferent neurons 
of the parasympathetic nervous system (vagus and pelvic nerves) and sympathetic nervous 
system (splanchnic nerves).  (Schematic diagram from Holzer et al. 2001).(Holzer et al., 
2001) 
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2.5.1 Oesophageal motility 
The musculature of the oesophagus is consisting of skeletal muscle in the upper third, a 
mixture of skeletal and smooth muscle in the middle, and smooth muscle only in the lower 
third. It‟s given task is to transport the swallowed food into the stomach. The two (upper and 
lower) oesophageal sphincters will relax and open after swallowing the food (a voluntary 
act) while a peristaltic contraction propels the food bolus (Mittal and Bhalla, 2004). The 
sphincters close after the contraction has swept through the entire length of the oesophagus. 
Peristalsis in the upper skeletal muscle part of the oesophagus is the consequence of the 
sequential activation of neurons in the nucleus ambigus, one of the vagal motor nuclei. 
Peristalsis in the smooth muscle part of the esophagus is mediated at the level of the 
dorsomotor nucleus of the vagal nerve and at the level of the myenteric plexus (Mittal and 
Bhalla, 2004).  
2.5.2 Gastric emptying 
The fundus, the upper part of the stomach, is involved mainly in the accommodation of 
food. The underlying relaxation of the proximal gastric wall seems to be mediated by 
inhibitory vagal neurons. This is because the reflex is abolished in vagotomy patients. 
Digestible substances reached an essentially liquid form when they are emptied from the 
stomach (Minami and McCALLUM, 1984).  
The antrum which is the distal part of the stomach, responsible for reducing solids form to 
the required fluid form. The antrum is also controlled by neuronal and humoral mechanisms. 
The rate of gastric emptying influences by the composition of the gastric contents. Neutral, 
isoosmolar, and calorically inert fluids empty fast.   
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Meanwhile hypertonic fluids containing acid, fat or certain amino acids delay gastric 
emptying (Minami and McCALLUM, 1984). 
2.5.3  Gastrointestinal motility 
Regarding the small bowel motility, it can be subdivided into interdigestive (fasting) and 
digestive (feeding) motility patterns (Fruhwald et al., 2007). 
The interdigestive motility pattern, the migrating motor complex (MMC), starts several 
hours after a meal. It has passed through the stomach and small intestine, progresses to the 
distal ileum. It consists of three distinct phases that are repeated approx. every 2 h: phase I is 
a period of quiescence (45–60 min), phase II a period of irregular contractions with a 
duration of 30–45 min, and phase III a period of regular, propulsive activity that lasts 5–15 
min (Fruhwald et al., 2007).  However, the duration of these MMC periods demonstrates 
enormous inter and intraindividual variability. Now all three phases of interdigestive 
motility are referred to as the MMC where previously only the phase III was subsumed 
under this term. 
A new one MMC begins in the stomach, by the time one ends in the ileum. A typical MMC 
pattern is important for the purging of the small bowel. Remaining food particles and 
indigestible residues are swept to the distal part of the small bowel and into the colon during 
phase III. An undisturbed MMC also important  play a role in protection against bacterial 
overgrowth of remaining food particles in the small bowel (Fruhwald et al., 2007). The 
MMC is controlled by the ENS and modulated by regulatory peptides. Disconnection of the 
extrinsic nerve supply does not interrupt the MMC pattern (Sana, 1985). Motilin is one of 
the MMC-regulating peptides. Intravenous administration of motilin or the motilin receptor 
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agonist erythromycin initiates phase III activity in the antroduodenal region. Meanwhile 
somatostatin and other substances can initiate phase III activity in the duodenum (Husebye, 
1999). An absence of the MMC indicates severe enteric dysfunction, while the presence of 
the MMC is thought to predict a successful outcome of enteral feeding (Schippers et al., 
1991). 
Interdigestive motility pattern disrupted by meal ingestion and replaces it with 
accommodation, stationary motility (segmental contractions and pendular movements) and 
propulsive peristalsis (Holzer et al., 2001). Accommodation denotes to an active relaxation 
of the fundus in response to food intake. Accommodation is also present in the small bowel 
and colon.  Filling of the bowel initiates a descending inhibitory reflex pathway (Costa et al., 
2000). Stationary contractions mix the food with the secretions of the gut and subsequently 
improve its contact with the mucosa of the small intestine to allow absorption of luminal 
contents. These stationary contractions are due to pendular movements of the longitudinal 
muscle and segmental contractions of the circular muscle (Fruhwald et al., 2007). Their 
rhythm derives from the interstitial cells of Cajal. These cells are innervated by excitatory 
and inhibitory motor neurons Therefor important as transducers of the ENS output to the 
musculature (Huizinga et al., 2000). Their oscillating membrane potential, transmitted 
electrically to the adjacent smooth muscle layers then initiates slow waves with a frequency 
of 10/min. These slow waves determine the frequency of the muscular contractions. 
Distortion of the mucosal villi or distension of the gut wall initiates propulsive peristalsis. 
These propulsive peristalsis involves a contraction of the circular muscle orally and 
relaxation aborally of the site of the stimulus (Fruhwald et al., 2007). The propulsive 
peristaltic wave moves only a few centimeters in order to forward the chyme, but not as far 
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as phase III of the MMC in the interdigestive motility pattern. The digestive pattern is 
lasting for several hours after ingestion of a meal. The duration seems to depend primarily 
on the caloric load of the food: the higher the caloric load, the longer the duration is 
(Ouyang et al., 1989). 
 
2.6: Classification of constipation 
Constipation can be divided into primary and secondary causes. 
2.6.1: Primary constipation 
Primary constipation can be classified into three groups: normal transit constipation, slow 
transit constipation, and anorectal dysfunction. Normal transit constipation is the most 
common, also known as functional constipation (Rao, 2009). 
Stool passes through the colon at a normal rate in patients with functional constipation. 
Second type of constipation - slow transit constipation is characterized by prolonged delay 
in the passage of stool through the colon (Rao, 2009). Patients may complain of abdominal 
bloating and infrequent bowel movements (Koch et al., 1997). The causes for slow transit 
constipation are unclear; therefore the postulation mechanisms include abnormalities of the 
myenteric plexus, defective cholinergic innervation, and anomalies of the noradrenergic 
neuromuscular transmission system (Rao, 2009). Anorectal dysfunction is the inefficient 
coordination of the pelvic musculature in the evacuation mechanism (Rao et al., 1998). 
These patients are more likely to complain of a feeling of incomplete evacuation, a sense of 
obstruction, or a need for digital manipulation.  
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2.6.2: Secondary constipation 
Table 1 : Lists medical and psychiatric conditions that are potential causes of secondary 
constipation (Hsieh, 2005). 
Causes of Secondary Constipation 
Endocrine and metabolic diseases 
Diabetes mellitus 
Hypercalcaemia 
Hyperparathyroidism 
Hypothyroidism 
Uraemia 
Myopathic conditions 
Amyloidosis 
Myotonic dystrophy 
Scleroderma 
 
Structural abnormalities 
Anal fissures, strictures, 
haemorrhoids 
Colonic strictures 
Inflammatory bowel disease 
Obstructive colonic mass lesions 
Rectal prolapse or rectocele 
Neurologic diseases 
Autonomic neuropathy 
Cerebrovascular disease 
Hirschsprung‟s disease 
Multiple sclerosis 
Parkinson‟s disease 
Spinal cord injury, tumors 
Psychological conditions 
Anxiety 
Depression 
Somatization 
Other 
Irritable bowel syndrome 
Pregnancy 
 
20 
 
 A thorough history and physical examination may exclude these conditions. A consensus 
guideline from the American Gastroenterological Association (AGA) also recommends that 
most patients have tests for a complete blood count and serum glucose, thyroid stimulating 
hormone, calcium, and creatinine levels. A sigmoidoscopy or colonoscopy to exclude colon 
cancer is indicated in patients older than 50 years who have not had a recent examination 
and in those with concomitant rectal bleeding or weight loss (Locke et al., 2000). The use of 
medications, especially those that affect the central nervous system, nerve conduction, and 
smooth muscle function are the important secondary causes of constipation. The most 
common medicines associated with constipation are listed in Table 2 (Prather and Ortiz-
Camacho, 1998).   
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Table 2: Medications commonly associated with secondary constipation (Prather and Ortiz-
Camacho,1998) 
 
 
 
 
 
 
 
 
Medications commonly associated with secondary constipation 
 
Anticholinergics 
Antidepressants 
Antihistamines 
Calcium channel blockers 
Opioids 
Psychotropics 
Sympathomimetics 
 
 
Clonidine (Catapres) 
Diuretics 
Iron 
Levodopa (Larodopa) 
Narcotics 
Nonsteroidal anti-inflammatory drugs 
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2.7 Constipation in Intensive Care Unit 
 
2.7.1 Definition 
Constipation was defined as „failure of the bowel to open for three consecutive 
days‟(Mostafa et al., 2003), (Dorman et al., 2004).  
This definition been used because it may be the most sensitive (Nassar Jr et al., 2009).  
A „normal‟ bowel function varies considerably. It is defined as „the maintenance of the 
patients usual bowel habit; the easy passage of (normally soft) stool, as frequently as is usual 
for the individual (Shepherd, 2000). However, Powell and Rigby et al state that normal 
bowel function should be at least twice per week (Powell and Rigby, 2000).  Action should 
be taken if the patient has not had their bowels opened in the last 3 days as constipation been 
occurred. A 3 days time frame permits for stabilization of the patient and the establishment 
of enteral feed (Dorman et al., 2004).  
2.7.2  Incidence and risk factors 
Constipation has received very little attention even though gastrointestinal motility disorders 
are common in critically ill patients. Incidence of constipation in ICU setting is variable, 
ranging from 50% to 83%.  
Patanwala studied 50% of patient did not have a bowel movement during the first 96 hours 
of medical ICU admission (Patanwala et al., 2006). Meanwhile Nassar Jr presented that 
constipation occurred in 69.9% of the patients (Nassar et al., 2009). 
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 Mostafa showed the higher result for incidence of constipation in critical care, which was 
83% (Mostafa et al., 2003). The difference in term of incidence percentage most likely due 
to the sensitiveness of the chosen criteria.   
Criteria that been used to look for incidence of constipation in intensive care are; all patients 
admitted to the ICU and who stayed for 3 or more days in ICU. This criterion because the 
previous study that addressed constipation in ICU setting defined constipation as a “failure 
of bowel to function for 3 consecutive days” (Mostafa et al., 2003). Patients were excluded 
if they did not stay in ICU for 3 or more days because of rapid recovery or death. Bowel 
surgery patients were also excluded (Nassar Jr et al., 2009).  
There are many elements that may contribute to constipation in critically ill patients. Present 
of shock causes splanchnic hypoperfusion, which is associated with impaired 
gastrointestinal motility. More common condition which is electrolyte disturbances, mainly 
hypokalemia and hypomagnesemia, are also associated with decreased in intestinal motility. 
Meanwhile Chappell and colleague revealed that major contributing factors on constipation 
in the intensive care unit are parenteral nutrition, mechanical ventilation, hypoperfusion, 
shock, dehydration, secretion of inflammatory mediators as well as endogenous and 
exogenous opioids (Chappell et al., 2008) 
Opioid-induced bowel dysfunction includes delayed gastric emptying accompanied by 
increased gastroesophageal reflux, as well as constipation (Thomas, 2008). Opioid such as 
fentanyl and morphine are the commonest prescribed analgesics in ICU. These opioids can 
inhibit intestinal motility and at the same time have a venodilator property. The venodilator 
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property can decrease venous return and, maybe, impair perfusion to a great level 
subsequently lead to constipation. (Fruhwald et al., 2007). 
Meanwhile, immobility, lack of fibre in diet, dehydration and factors such as lack of access 
to appropriate facilities can also lead to constipation. In addition, in ICU critically ill 
patients cannot mobilize to the toilet, response to the urge or strain to defecate (Mostafa et 
al., 2003). 
Martindale and Maerz et al had done the study which first to demonstrate that the early 
beginning of enteral nutrition is associated with a decreased incidence of constipation. 
Enteral nutrition demonstrated that better preserves the gastrointestinal mucosal structure 
and function based on experimental and clinical studies (Martindale and Maerz, 2006). 
Apart from that, defecation also may be seen as a sign of maintenance of gastrointestinal 
function. This is because there is a tendency to face impaired gastrointestinal motility as a 
manifestation of multiple organ dysfunctions. Therefore early enteral nutrition may be seen 
as a protective factor.  
Other than that, antibiotic therapy was not associated with either increase or decrease in 
incidence of constipation (Nassar Jr et al., 2009). 
2.7.3: Implication in the critically ill patient  
Observational studies done by Nassar and colleague had found a correlation between 
constipation, organ dysfunction, prolonged length of stay and failure to wean from 
mechanical ventilation, although results diverge among studies (Nassar Jr et al., 2009). 
Mostafa et al said constipation can give rise few implications in patients such as more 
